Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study
To evaluate local tumor control and survival data after transarterial chemoembolization with different drug combinations in the palliative treatment of liver metastases in patients with colorectal cancer. The study was approved by institutional review board, and informed consent was obtained from al...
Gespeichert in:
| Veröffentlicht in: | Radiology 2009, Vol.250 (1), p.281-289 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 289 |
|---|---|
| container_issue | 1 |
| container_start_page | 281 |
| container_title | Radiology |
| container_volume | 250 |
| creator | VOGL, Thomas J GRUBER, Tatjana BALZER, Jörn O EICHLER, Katrin HAMMERSTINGL, Renate ZANGOS, Stefan |
| description | To evaluate local tumor control and survival data after transarterial chemoembolization with different drug combinations in the palliative treatment of liver metastases in patients with colorectal cancer.
The study was approved by institutional review board, and informed consent was obtained from all patients included in the study. A total of 463 patients (mean age, 62.5 years; range, 34.7-88.1 years) with unresectable liver metastases of colorectal cancer that did not respond to systemic chemotherapy were repeatedly treated with chemoembolization in 4-week intervals. In total, 2441 chemoembolization procedures were performed (mean, 5.3 sessions per patient). Of 463 patients, 67.4% had multiple (five or more) metastases, 8% had one metastasis, 10.4% had two metastases, and 14.3% had three or four metastases. The local chemotherapy protocol consisted of mitomycin C alone (n = 243), mitomycin C with gemcitabine (n = 153), or mitomycin C with irinotecan (n = 67). Embolization was performed with lipiodol and starch microspheres for vessel occlusion. Tumor response was evaluated with magnetic resonance imaging. The change in tumor size was calculated and the response was evaluated according to the Response Evaluation Criteria in Solid Tumors. Survival rates from first diagnosis and from first chemoembolization session were calculated according to the Kaplan-Meier method. Follow-up imaging was performed until patient death.
Evaluation of local tumor control resulted in partial response (68 patients [14.7%]), stable disease (223 patients [48.2%]), and progressive disease (172 patients [37.1%]). The 1-year survival rate after chemoembolization was 62%, and the 2-year survival rate was 28%. Median survival from date of diagnosis of liver metastases was 38 months and from the start of chemoembolization treatment was 14 months. There was no statistically significant difference between the three treatment protocols.
Chemoembolization is a minimally invasive therapy option for palliative treatment of liver metastases in patients with colorectal cancer, with similar results among three chemoembolization protocols. |
| doi_str_mv | 10.1148/radiol.2501080295 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66747401</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66747401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-1829f73fd3096699f27b7078d1bf11708b60993907d19a9cd1003b426fdf18af3</originalsourceid><addsrcrecordid>eNpFkFFLHDEQx0Ox1NP2A_hS8mLf1maS3U3imxxWhZOWap-X7GaCkd3NNckW9NM3xx0KAwPDb_7M_Ag5A3YBUKvv0VgfxgveMGCKcd18ICtouKxAQHNEVowJUaka9DE5SemZMagbJT-RY9BMc6b1iiy_cYsmo6WP0czJxIzRm5Gun3AKOPVh9K8m-zBTP9P8hAUr-IRzpsHRjf-Hkd5jNqkUpt1sHcYQcci7EDMPGC_prxjStowKTR_yYl8-k4_OjAm_HPop-fPj-nF9W21-3tytrzbVICTPFSiunRTOCqbbVmvHZS-ZVBZ6ByCZ6tvyhNBMWtBGDxbKx33NW2cdKOPEKfm2z93G8HfBlLvJpwHH0cwYltS1raxlzaCAsAeHcmqK6Lpt9JOJLx2wbue627vu3l2Xna-H8KWf0L5vHOQW4PwAmDSY0RXBg09vHIdG1KCU-A9g-4mP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66747401</pqid></control><display><type>article</type><title>Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>VOGL, Thomas J ; GRUBER, Tatjana ; BALZER, Jörn O ; EICHLER, Katrin ; HAMMERSTINGL, Renate ; ZANGOS, Stefan</creator><creatorcontrib>VOGL, Thomas J ; GRUBER, Tatjana ; BALZER, Jörn O ; EICHLER, Katrin ; HAMMERSTINGL, Renate ; ZANGOS, Stefan</creatorcontrib><description>To evaluate local tumor control and survival data after transarterial chemoembolization with different drug combinations in the palliative treatment of liver metastases in patients with colorectal cancer.
The study was approved by institutional review board, and informed consent was obtained from all patients included in the study. A total of 463 patients (mean age, 62.5 years; range, 34.7-88.1 years) with unresectable liver metastases of colorectal cancer that did not respond to systemic chemotherapy were repeatedly treated with chemoembolization in 4-week intervals. In total, 2441 chemoembolization procedures were performed (mean, 5.3 sessions per patient). Of 463 patients, 67.4% had multiple (five or more) metastases, 8% had one metastasis, 10.4% had two metastases, and 14.3% had three or four metastases. The local chemotherapy protocol consisted of mitomycin C alone (n = 243), mitomycin C with gemcitabine (n = 153), or mitomycin C with irinotecan (n = 67). Embolization was performed with lipiodol and starch microspheres for vessel occlusion. Tumor response was evaluated with magnetic resonance imaging. The change in tumor size was calculated and the response was evaluated according to the Response Evaluation Criteria in Solid Tumors. Survival rates from first diagnosis and from first chemoembolization session were calculated according to the Kaplan-Meier method. Follow-up imaging was performed until patient death.
Evaluation of local tumor control resulted in partial response (68 patients [14.7%]), stable disease (223 patients [48.2%]), and progressive disease (172 patients [37.1%]). The 1-year survival rate after chemoembolization was 62%, and the 2-year survival rate was 28%. Median survival from date of diagnosis of liver metastases was 38 months and from the start of chemoembolization treatment was 14 months. There was no statistically significant difference between the three treatment protocols.
Chemoembolization is a minimally invasive therapy option for palliative treatment of liver metastases in patients with colorectal cancer, with similar results among three chemoembolization protocols.</description><identifier>ISSN: 0033-8419</identifier><identifier>EISSN: 1527-1315</identifier><identifier>DOI: 10.1148/radiol.2501080295</identifier><identifier>PMID: 19092099</identifier><identifier>CODEN: RADLAX</identifier><language>eng</language><publisher>Oak Brook, IL: Radiological Society of North America</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Camptothecin - administration & dosage ; Camptothecin - analogs & derivatives ; Chemoembolization, Therapeutic - methods ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - therapy ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Disease Progression ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Infusions, Intra-Arterial ; Investigative techniques, diagnostic techniques (general aspects) ; Liver Neoplasms - diagnosis ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Liver Neoplasms - secondary ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Mitomycin - administration & dosage ; Palliative Care ; Prospective Studies ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Survival Rate ; Tomography, Spiral Computed ; Tumors</subject><ispartof>Radiology, 2009, Vol.250 (1), p.281-289</ispartof><rights>2009 INIST-CNRS</rights><rights>(c) RSNA, 2009.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-1829f73fd3096699f27b7078d1bf11708b60993907d19a9cd1003b426fdf18af3</citedby><cites>FETCH-LOGICAL-c372t-1829f73fd3096699f27b7078d1bf11708b60993907d19a9cd1003b426fdf18af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21534188$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19092099$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VOGL, Thomas J</creatorcontrib><creatorcontrib>GRUBER, Tatjana</creatorcontrib><creatorcontrib>BALZER, Jörn O</creatorcontrib><creatorcontrib>EICHLER, Katrin</creatorcontrib><creatorcontrib>HAMMERSTINGL, Renate</creatorcontrib><creatorcontrib>ZANGOS, Stefan</creatorcontrib><title>Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study</title><title>Radiology</title><addtitle>Radiology</addtitle><description>To evaluate local tumor control and survival data after transarterial chemoembolization with different drug combinations in the palliative treatment of liver metastases in patients with colorectal cancer.
The study was approved by institutional review board, and informed consent was obtained from all patients included in the study. A total of 463 patients (mean age, 62.5 years; range, 34.7-88.1 years) with unresectable liver metastases of colorectal cancer that did not respond to systemic chemotherapy were repeatedly treated with chemoembolization in 4-week intervals. In total, 2441 chemoembolization procedures were performed (mean, 5.3 sessions per patient). Of 463 patients, 67.4% had multiple (five or more) metastases, 8% had one metastasis, 10.4% had two metastases, and 14.3% had three or four metastases. The local chemotherapy protocol consisted of mitomycin C alone (n = 243), mitomycin C with gemcitabine (n = 153), or mitomycin C with irinotecan (n = 67). Embolization was performed with lipiodol and starch microspheres for vessel occlusion. Tumor response was evaluated with magnetic resonance imaging. The change in tumor size was calculated and the response was evaluated according to the Response Evaluation Criteria in Solid Tumors. Survival rates from first diagnosis and from first chemoembolization session were calculated according to the Kaplan-Meier method. Follow-up imaging was performed until patient death.
Evaluation of local tumor control resulted in partial response (68 patients [14.7%]), stable disease (223 patients [48.2%]), and progressive disease (172 patients [37.1%]). The 1-year survival rate after chemoembolization was 62%, and the 2-year survival rate was 28%. Median survival from date of diagnosis of liver metastases was 38 months and from the start of chemoembolization treatment was 14 months. There was no statistically significant difference between the three treatment protocols.
Chemoembolization is a minimally invasive therapy option for palliative treatment of liver metastases in patients with colorectal cancer, with similar results among three chemoembolization protocols.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Camptothecin - administration & dosage</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - therapy</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Infusions, Intra-Arterial</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Liver Neoplasms - diagnosis</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mitomycin - administration & dosage</subject><subject>Palliative Care</subject><subject>Prospective Studies</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Survival Rate</subject><subject>Tomography, Spiral Computed</subject><subject>Tumors</subject><issn>0033-8419</issn><issn>1527-1315</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkFFLHDEQx0Ox1NP2A_hS8mLf1maS3U3imxxWhZOWap-X7GaCkd3NNckW9NM3xx0KAwPDb_7M_Ag5A3YBUKvv0VgfxgveMGCKcd18ICtouKxAQHNEVowJUaka9DE5SemZMagbJT-RY9BMc6b1iiy_cYsmo6WP0czJxIzRm5Gun3AKOPVh9K8m-zBTP9P8hAUr-IRzpsHRjf-Hkd5jNqkUpt1sHcYQcci7EDMPGC_prxjStowKTR_yYl8-k4_OjAm_HPop-fPj-nF9W21-3tytrzbVICTPFSiunRTOCqbbVmvHZS-ZVBZ6ByCZ6tvyhNBMWtBGDxbKx33NW2cdKOPEKfm2z93G8HfBlLvJpwHH0cwYltS1raxlzaCAsAeHcmqK6Lpt9JOJLx2wbue627vu3l2Xna-H8KWf0L5vHOQW4PwAmDSY0RXBg09vHIdG1KCU-A9g-4mP</recordid><startdate>2009</startdate><enddate>2009</enddate><creator>VOGL, Thomas J</creator><creator>GRUBER, Tatjana</creator><creator>BALZER, Jörn O</creator><creator>EICHLER, Katrin</creator><creator>HAMMERSTINGL, Renate</creator><creator>ZANGOS, Stefan</creator><general>Radiological Society of North America</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2009</creationdate><title>Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study</title><author>VOGL, Thomas J ; GRUBER, Tatjana ; BALZER, Jörn O ; EICHLER, Katrin ; HAMMERSTINGL, Renate ; ZANGOS, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-1829f73fd3096699f27b7078d1bf11708b60993907d19a9cd1003b426fdf18af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Camptothecin - administration & dosage</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - therapy</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Infusions, Intra-Arterial</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Liver Neoplasms - diagnosis</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mitomycin - administration & dosage</topic><topic>Palliative Care</topic><topic>Prospective Studies</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Survival Rate</topic><topic>Tomography, Spiral Computed</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VOGL, Thomas J</creatorcontrib><creatorcontrib>GRUBER, Tatjana</creatorcontrib><creatorcontrib>BALZER, Jörn O</creatorcontrib><creatorcontrib>EICHLER, Katrin</creatorcontrib><creatorcontrib>HAMMERSTINGL, Renate</creatorcontrib><creatorcontrib>ZANGOS, Stefan</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VOGL, Thomas J</au><au>GRUBER, Tatjana</au><au>BALZER, Jörn O</au><au>EICHLER, Katrin</au><au>HAMMERSTINGL, Renate</au><au>ZANGOS, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study</atitle><jtitle>Radiology</jtitle><addtitle>Radiology</addtitle><date>2009</date><risdate>2009</risdate><volume>250</volume><issue>1</issue><spage>281</spage><epage>289</epage><pages>281-289</pages><issn>0033-8419</issn><eissn>1527-1315</eissn><coden>RADLAX</coden><abstract>To evaluate local tumor control and survival data after transarterial chemoembolization with different drug combinations in the palliative treatment of liver metastases in patients with colorectal cancer.
The study was approved by institutional review board, and informed consent was obtained from all patients included in the study. A total of 463 patients (mean age, 62.5 years; range, 34.7-88.1 years) with unresectable liver metastases of colorectal cancer that did not respond to systemic chemotherapy were repeatedly treated with chemoembolization in 4-week intervals. In total, 2441 chemoembolization procedures were performed (mean, 5.3 sessions per patient). Of 463 patients, 67.4% had multiple (five or more) metastases, 8% had one metastasis, 10.4% had two metastases, and 14.3% had three or four metastases. The local chemotherapy protocol consisted of mitomycin C alone (n = 243), mitomycin C with gemcitabine (n = 153), or mitomycin C with irinotecan (n = 67). Embolization was performed with lipiodol and starch microspheres for vessel occlusion. Tumor response was evaluated with magnetic resonance imaging. The change in tumor size was calculated and the response was evaluated according to the Response Evaluation Criteria in Solid Tumors. Survival rates from first diagnosis and from first chemoembolization session were calculated according to the Kaplan-Meier method. Follow-up imaging was performed until patient death.
Evaluation of local tumor control resulted in partial response (68 patients [14.7%]), stable disease (223 patients [48.2%]), and progressive disease (172 patients [37.1%]). The 1-year survival rate after chemoembolization was 62%, and the 2-year survival rate was 28%. Median survival from date of diagnosis of liver metastases was 38 months and from the start of chemoembolization treatment was 14 months. There was no statistically significant difference between the three treatment protocols.
Chemoembolization is a minimally invasive therapy option for palliative treatment of liver metastases in patients with colorectal cancer, with similar results among three chemoembolization protocols.</abstract><cop>Oak Brook, IL</cop><pub>Radiological Society of North America</pub><pmid>19092099</pmid><doi>10.1148/radiol.2501080295</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0033-8419 |
| ispartof | Radiology, 2009, Vol.250 (1), p.281-289 |
| issn | 0033-8419 1527-1315 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66747401 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Camptothecin - administration & dosage Camptothecin - analogs & derivatives Chemoembolization, Therapeutic - methods Colorectal Neoplasms - diagnosis Colorectal Neoplasms - mortality Colorectal Neoplasms - therapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Disease Progression Female Gastroenterology. Liver. Pancreas. Abdomen Humans Infusions, Intra-Arterial Investigative techniques, diagnostic techniques (general aspects) Liver Neoplasms - diagnosis Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - secondary Liver. Biliary tract. Portal circulation. Exocrine pancreas Magnetic Resonance Imaging Male Medical sciences Middle Aged Mitomycin - administration & dosage Palliative Care Prospective Studies Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Survival Rate Tomography, Spiral Computed Tumors |
| title | Repeated Transarterial Chemoembolization in the Treatment of Liver Metastases of Colorectal Cancer: Prospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T01%3A18%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20Transarterial%20Chemoembolization%20in%20the%20Treatment%20of%20Liver%20Metastases%20of%20Colorectal%20Cancer:%20Prospective%20Study&rft.jtitle=Radiology&rft.au=VOGL,%20Thomas%20J&rft.date=2009&rft.volume=250&rft.issue=1&rft.spage=281&rft.epage=289&rft.pages=281-289&rft.issn=0033-8419&rft.eissn=1527-1315&rft.coden=RADLAX&rft_id=info:doi/10.1148/radiol.2501080295&rft_dat=%3Cproquest_cross%3E66747401%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66747401&rft_id=info:pmid/19092099&rfr_iscdi=true |